Sphingosine
|
Basic information |
| Metabolite name | Sphingosine |
 | HMDB0000252 |
 |
C00319 |
 |
5353955 |
| Synonyms | D-sphingosine |
| No. of studies | 14 |
|
Basic information |
| Metabolite name | Sphingosine |
| HMDB0000252 |
|
C00319 |
|
5353955 |
| Synonyms | D-sphingosine |
| No. of studies | 14 |
|
Relationship between Sphingosine and depression (count: 14) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M1032 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M104 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M1072 | Type1 | CUMS group vs. control group | Intestine | Cynomolgus monkey | Up |
| Study M1098 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M1098 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1098 | Type2 | CUMS + L-theanine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M1105 | Type1 | psychological stress group vs. control group | Faece | C57BL/6 J mouse | Down |
| Study M181 | Type3 | venlafaxine group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
| Study M454 | Type1 | vascular depression model group vs. control group | Hippocampus | ICR mouse | Down |
| Study M454 | Type2 | vascular depression model + YXST group vs. vascular depression model group | Hippocampus | ICR mouse | Up |
| Study M512 | Type1 | CUMS group vs. control group | Plasma | Goto-Kakizaki rat | Up |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M618 | Type3 | chronic paroxetine group vs. chronic paroxetine control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M618 | Type3 | acute desipramine group vs. acute desipramine control group | Hippocampus | Sprague-Dawley rat | Down |
| Study M618 | Type3 | chronic desipramine group vs. chronic desipramine control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M618 | Type3 | chronic paroxetine group vs. chronic paroxetine control group | Prefrontal cortex | Sprague-Dawley rat | Down |
| Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
| Study M846 | Type1 | postpartum depression model group vs. control group | Faece | BALB/c mouse | Down |
| Study M870 | Type1 | CRS group vs. control group | Brain | C57BL/6 mouse | Down |
| Study M870 | Type2 | CRS + sertraline group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M870 | Type2 | CRS + middle dose of Jia Wei Xiao Yao San group vs. CRS group | Brain | C57BL/6 mouse | Up |
| Study M927 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Down |